A. Menarini Industrie Farmaceutiche Riunite Srl-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013150)
◆英語タイトル:A. Menarini Industrie Farmaceutiche Riunite Srl - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013150
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:68
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company’s products portfolio is focused on a several therapeutic and wellness areas including allergy, andrology, antinfective areas, cardiovascular areas, gastrointestinal disorders, gynecology and women’s wellness, respiratory areas, rheumatology, osteoporosis, dermatology and personal care, energy supplements and multivitamins, and others. Menarini operates through its manufacturing sites, research and development centers and has presence across Europe and Asia, Africa, Central and South America. It distributes products across several countries worldwide through partners and distributors. Menarini is headquartered in Florence, Italy.

A. Menarini Industrie Farmaceutiche Riunite Srl – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2011 to YTD 2017 12
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For US$80 Million 16
Invida Acquires Dermatology And Primary Care Product Portfolios From Shalaks Pharma For US$20 Million 17
Partnerships 19
Melinta Therapeutics Enters into Agreement with Menarini 19
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 20
Menarini Asia-Pacific Enters into Agreement with Merck 21
Menarini Forms Joint Venture with BiosYnth 22
Moberg Extends Distribution Agreement with Menarini for Emtrix 23
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 24
Moberg Pharma Extends Distribution Agreement With Menarini 25
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 26
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 27
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 28
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 30
Moberg Derma Enters Into Co-Marketing Agreement With Menarini For Emtrix 31
Sinclair Pharma Extends Co-Marketing Agreement With Invida 32
Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 33
Invida Group Enters Into Agreement With F. Hoffmann-La Roche 34
Licensing Agreements 36
Berlin-Chemie Enters into Licensing Agreement with Selvita 36
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 37
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 38
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 39
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 40
Vivus Enters Into Licensing Agreement With Menarini For Spedra 41
Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 43
FAES Farma Enters into License Agreement with Menarini For Bilastina 44
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 45
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 46
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 48
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 49
Orexo Enters Into Licensing Agreement With Invida Group For Abstral 50
GlaxoSmithKline Enters Into Licensing Agreement With Menarini For Bilastine 51
Acquisition 52
Menarini Group Plans To Acquire Indian Pharma Company 52
Menarini Group Acquires Invida 53
A. Menarini Industrie Farmaceutiche Riunite Srl – Key Competitors 55
A. Menarini Industrie Farmaceutiche Riunite Srl – Key Employees 56
A. Menarini Industrie Farmaceutiche Riunite Srl – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Joint Venture 60
Recent Developments 61
Strategy And Business Planning 61
Mar 13, 2017: Menarini Arrives In Columbia And Peru Two New Offices For A Stronger Connection Between Two Continents 61
Jan 18, 2017: Menarini In Turkey: +25% Growth In 2016 And New Headquarters In Istanbul 62
Corporate Communications 63
Jun 29, 2017: Menarini Increases Number of Members of the Board – for the First Time External Members In Majority 63
Product News 64
Apr 12, 2017: Menarini Brings Sirmione Thermal Water Into Italian Homes 64
03/17/2017: Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia 65
Product Approvals 66
Apr 18, 2016: Selvita files IND Application for its novel, dual PIM/FLT3 inhibitor in AML 66
Other Significant Developments 67
Sep 06, 2016: Menarini Invests In Research And Production In Italy And In Germany It Expands Its Location 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Key Facts, 2016 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Deals By Therapy Area, 2011 to YTD 2017 10
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2011 to YTD 2017 12
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For US$80 Million 16
Invida Acquires Dermatology And Primary Care Product Portfolios From Shalaks Pharma For US$20 Million 17
Melinta Therapeutics Enters into Agreement with Menarini 19
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 20
Menarini Asia-Pacific Enters into Agreement with Merck 21
Menarini Forms Joint Venture with BiosYnth 22
Moberg Extends Distribution Agreement with Menarini for Emtrix 23
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 24
Moberg Pharma Extends Distribution Agreement With Menarini 25
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 26
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 27
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 28
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 30
Moberg Derma Enters Into Co-Marketing Agreement With Menarini For Emtrix 31
Sinclair Pharma Extends Co-Marketing Agreement With Invida 32
Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 33
Invida Group Enters Into Agreement With F. Hoffmann-La Roche 34
Berlin-Chemie Enters into Licensing Agreement with Selvita 36
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 37
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 38
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 39
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 40
Vivus Enters Into Licensing Agreement With Menarini For Spedra 41
Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 43
FAES Farma Enters into License Agreement with Menarini For Bilastina 44
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 45
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 46
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 48
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 49
Orexo Enters Into Licensing Agreement With Invida Group For Abstral 50
GlaxoSmithKline Enters Into Licensing Agreement With Menarini For Bilastine 51
Menarini Group Plans To Acquire Indian Pharma Company 52
Menarini Group Acquires Invida 53
A. Menarini Industrie Farmaceutiche Riunite Srl, Key Competitors 55
A. Menarini Industrie Farmaceutiche Riunite Srl, Key Employees 56
A. Menarini Industrie Farmaceutiche Riunite Srl, Subsidiaries 57
A. Menarini Industrie Farmaceutiche Riunite Srl, Joint Venture 60

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ A. Menarini Industrie Farmaceutiche Riunite Srl-製薬・医療分野:企業M&A・提携分析(A. Menarini Industrie Farmaceutiche Riunite Srl - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆